CD274 and neoplasm: Ipilimumab is approved in combination with nivolumab, with a favourable outcome compared with ipilimumab monotherapy, although the superiority of combination therapy over anti-PD-1 monotherapy is less when tumour PD-L1 expression is greater than 5% 12,13.